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TITLE OF THESIS: “COX-2 expression in endometrial carcinoma 
and its correlation with clinicopathological parameters” 
 
 
ABSTRACT: 
 
Endometrial cancer is a common cancer occurring in postmenopausal women. The 
important prognostic factors include FIGO stage, histologic grade, cell type, 
myometrial invasion and lymphovascular invasion. The advent of targeted therapy 
has led to a realm of studies on immunomarkers in various cancers including 
endometrial cancer. Cyclooxygenase-2 (COX-2) is one among the 
immunomarkers being studied in endometrial carcinoma. 
We studied 37 uterine cancers diagnosed on hysterectomy specimens and found 
that 36 cases (97%) were positive for COX-2 and 29 showed overexpression 
(78%). Majority of the endometrioid carcinomas (76%) overexpressed COX-2. 
Overexpression was 100% in all the four non-endometrioid carcinomas, tumors 
with a nuclear grade of III and tumors presenting in stage II and above. Although 
the results were close to statistical significance, the observations are noteworthy.  
 
KEY WORDS: Endometrial cancer, Cyclooxygenase-2 (COX-2), overexpression. 
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Endometrial cancer is the fifth most common cancer among women 
worldwide and the ninth commonest cancer among women in India (1). It 
commonly occurs in postmenopausal women, with the median age being 63 
years at presentation. Less than 5% of the endometrial cancers occur in 
women below 40 years of    age (2). It is the seventh leading cause of cancer 
related death among women (1).  
Clinically, the smaller tumors are usually asymptomatic. The most common 
presentation is abnormal vaginal bleeding. Rare cases have been diagnosed 
incidentally from curetting or during an autopsy (3). Pelvic pain, when 
present reflects spread of tumor (2). The gold standard for diagnosis is 
histopathological study which can be established from tissues, obtained by 
endometrial curetting, hysteroscopic biopsy or hysterectomy specimens (4).  
80% of endometrial cancers are of Type I and they are associated with 
conditions characterized by prolonged exposure to estrogens (5). These 
include exogenous estrogens given for hormone replacement therapy, 
Tamoxifen therapy in breast cancer patients, increased endogenous estrogen 
exposure as in early menarche, late menopause, nulliparity, infertility, 
polycystic disease of ovary, obesity, diabetes and ovarian lesions associated 
with excessive and unopposed estrogen production as in granulosa cell 
tumor, thecoma, hyperthecosis and ovarian stromal hyperplasia (2).  
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Factors that influence the prognosis for endometrial cancers are FIGO stage, 
tumor grade, histologic type, myometrial invasion, lymph node status, 
vascular invasion and ER, PR status.  The advent of targeted gene therapy 
has shifted the focus of research into studying the expression of various 
immunomarkers in endometrial cancers. Cyclooxygenase-2 (COX-2) is one 
amongst them.  
COX-2 is an enzyme involved in the arachidonic acid pathway of 
inflammation. One of the end products of this pathway, the prostaglandins, 
has been thought to contribute to the inhibition of apoptosis and immune 
function, as well as the promotion of angiogenesis, invasion and 
metastasis(6).   
Studies have shown that, the expression of COX-2 increases with the 
spectrum of endometrial disease, starting from simple hyperplasia and 
progressing to complex hyperplasia with atypia and endometrial cancer. 
Even within endometrial cancers, their expression increases with worsening 
histological grade (7). Even the more aggressive squamous cell carcinomas 
have been found to show a more consistent association with COX-2 over 
expression (8).  
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We receive endometrial tissues of all these disease conditions. However, we 
have not studied expression of this immunomarker so far. Further, a 
literature search also did not reveal any publications on this immunomarker 
from South India. Hence, this study. 
Aims & Objectives 
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1. To identify the occurrence of endometrial cancer in the study period. 
2. To observe the age distribution and the clinical stage at presentation 
of the endometrial cancers.  
3. To observe the overexpression of the immunomarker COX-2 in the 
endometrial carcinoma tissues. 
4. To correlate the cases with overexpression of COX-2 with the 
clinicopathological parameters such as menstrual status, parity index, 
FIGO stage, histological type, grade of the tumour and myometrial 
invasion. 
Review of literature 
 
5 
 
 
UTERUS AND FALLOPIAN TUBES – A BRIEF OVERVIEW: 
The uterus and the fallopian tubes are derived from the mullerian duct and 
are said to form a single structural & functional unit. Their prime functions 
during the reproductive phase of life are: 
 Providing the site for fertilization  
 Implantation of blastocyst 
 Incubation of the embryo and fetus 
 Delivery of the fetus at term (9).  
They respond to the various hormonal stimuli as a single unit. 
Pathologically, the uterus, tubes and the ovarian surface epithelium form a 
single unit termed, the extended mullerian system and are affected by a 
similar group of neoplasms and metaplastic changes 
(10)
.    
EMBRYOLOGY OF THE UTERUS AND FALLOPIAN TUBES: 
The development of the male and female genital tracts takes place in two 
stages. 
1. The indifferent stage 
2. Specific sex differentiation (male or female) 
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1. THE INDIFFERENT STAGE: 
In the indifferent stage, the precursors of the internal genital organs of 
both the sexes are laid down and they are similar to those of the 
bipotential gonad. Following this stage, female embryos lose the male 
anlage and vice versa. Both these anlages are closely related to the 
developing urinary system and so anomalies of the genital tract are often 
associated with those of the urinary system 
(11)
.    
The mesonephric / Wolffian ducts and the urogenital sinus are well 
formed in the developing embryo by the sixth week. At this stage, the 
paramesonephric / mullerian ducts begin developing, by the invagination 
of the cealomic epithelium. The same also invests around the developing 
ovary. The distal ends of the mullerian ducts fuse in the midline and lose 
their medial walls resulting in a single cavity. This structure is called the 
uterovaginal primordium and it grows downwards towards the urogenital 
sinus 
(9)
.    
2. SPECIFIC SEX DIFFERENTIATION (MALE OR FEMALE) 
Sex differentiation depends on the gonad, whether it is the testis or the 
ovary. The developing testis in the male fetus, secretes testosterone 
which promotes the growth and differentiation of the Wolffian duct  
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into the male genital system. It also secretes antimullerian hormone, 
which causes the regression of the mullerian ducts. When there is no 
testosterone stimulation, the mullerian ducts persist and give rise to 
female genital organs. The uterus and upper third of vagina form from 
the fused end of the mullerian ducts while the fallopian tubes are formed 
from the unfused ends. 
The uterus and vagina are fully developed by the 21
st
 week of gestation. 
At this stage, the cervix is longer than the uterus. By birth, the uterus 
doubles in size, but the cervix remains larger in the prepubertal child. 
The homeobox gene family and the wingless gene family are said to be 
involved in these processes 
(9)
.    
THE UTERUS IN THE PRE-PUBERTAL PERIOD: 
At birth, the uterus measures about 4 cm. Its length is mostly constituted 
by the cervix. Maternal hormonal effect causes the newborn vagina to be 
thickened, with rugosity of the wall. The uterus grows in size up to two 
years of age and then stops till prepubertal changes start at the age of 
nine 
(12)
.    
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STRUCTURAL ANATOMY OF THE ADULT UTERUS: 
1. LOCATION: 
The uterus is a pelvic organ located behind the bladder and before the 
rectum. It is covered by peritoneum, which extends deeper in the 
posterior than the anterior aspect. Laterally, the peritoneum forms the 
broad ligament which ensheaths the fallopian tubes and the lymphatics 
and blood vessels of the uterus. The utero-ovarian ligament connects the 
ovary to the uterus. The other supports of the uterus are the cardinal 
ligaments, uterosacral ligaments and the pubocervical ligaments 
(9)
.    
2. GROSS ANATOMY:  
The uterus is a cavitated, pear shaped organ which is mostly muscular in 
nature. It measures approximately, 7x5x2.5cm. Its average weight is 40-
80gms. Uterine measurements vary with age, menstrual cycle phase and 
parity. The cervix in the adult uterus is smaller than the corpus. The 
uterine corpus is divided into four parts: 
i. Fundus 
ii. Cornu 
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iii. Body 
iv.  Lower uterine segment 
The fundus is located above an imaginary line connecting the origins of the 
tubes. The cornua are lateral to the fundus and this is where the intramural 
portions of the tubes lie. The body tapers downwards towards the lower 
uterine segment. The triangular uterine cavity is connected to the lumina of 
the fallopian tubes and the cervix.  The approximate length of the cavity is 6 
cm and it too varies with parity and age 
(13)
.     
The cylindrical cervix has an approximate length of 3-4 cm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
. Part of the cervix is seen to protrude into the upper portion of the vagina 
called the portiovaginalis and the rest is seen above the vagina, called the 
portiosupravagnalis. It encloses the endocervical canal. The cavity opens 
into the vagina through the external os and the portion of the cervix upto the 
external os is called the ectocervix. The endocervical canal opens into the 
uterus through the internal os. Plicae palmatae are gross appearances of the 
mucosal clefts seen in the endocervix 
(14)
.    
The uterus weighs more in a parous woman and the weight increases with 
parity. The vasculature is also more prominent than in nullipara. The 
cervical os, which is circular in the nullipara becomes slit-like in the  
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parous woman with an anterior and a posterior lip. The cervix in parous 
women may also show healed lacerations and ectocervical „erosions‟ that 
are caused by the presence of endocervical mucosa outside the external os. 
In postmenopausal women, the uterus decreases in size and weight. 
Sometimes the endocervical canal may even become obliterated. Hormone 
replacement therapy may delay these effects to some extent 
(9)
.    
3. BLOOD SUPPLY: 
The right and left uterine arteries supply the uterus. They branch at the 
isthumus into ascending and descending arteries. The ascending branches 
extend upward and anastamose with the arterial supply of the ovaries and 
the descending branches anastamose with those of the vagina. The arcuate 
arteries are formed in the subserosa from the ascending and descending 
arteries which in turn give rise to the radial arteries which penetrate through 
the myometrium. These in turn give rise to the straight arteries supplying the 
basal region of the endometrium and the spiral arteries which supply the rest 
of the endometrium 
(9)
.    
4. LYMPHATIC DRAINAGE: 
The lymphatic channels are seen close to the endometrial glands in the 
mucosa. In the myometrium and cervical stroma, the lymphatic channels of  
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both these regions often anastamose and reach the subserosal plexus. The 
draining nodes start at the parametrium and paracervical region and, go on 
to the inguinal nodes, obturator set of nodes, the hypogastric nodes, the 
external and common iliac nodes, the sacral nodes and finally into the aortic 
nodes 
(15). 
 
HORMONES THAT ACT ON THE UTERUS:  
At birth, secretion of endogenous hormones does not take place. However, 
estrogen produced by the mother may influence the uterine endometrium 
and the cervix transiently 
(12).
  
At puberty, the endogenous hormone secretion begins but is quite 
unpredictable for the first few years, resulting in anovulation and highly 
variable cycle lengths 
(16).
  
The regular menstrual cycle requires the participation of four different 
organs: 
1) The hypothalamus, which secretes the gonadotrophin releasing 
hormone (GnRH). 
2) The pituitary, which secretes follicle stimulating hormone (FSH) and 
luteinizing hormone (LH). 
3) The ovarian cortex, which produces estrogen and progesterone. 
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4) Endometrium, which responds to these steroid hormones. 
In the hypothalamus, the arcuate nucleus, releases GnRH in a pulsatile 
manner. This GnRH, controls the release of the pituitary hormones. FSH 
stimulates the secretion of estrogen by the ovarian follicles and LH, the 
secretion of progesterone by the corpus luteum. These in turn, suppress the 
secretion of the pituitary hormones by a negative feedback mechanism 
(17).
  
FOLLICULAR/PROLIFERATIVE PHASE: 
Prior to the starting of the menstrual period, the production of FSH 
increases. This causes the recruitment of follicles in the ovarian cortex. One 
of these follicles becomes dominant and converts circulating androgens into 
estrogens, mainly estradiol, in the presence of LH 
(18).
 Regulatory hormones, 
namely, activins and inhibins are also secreted by the ovarian follicles. 
Inhibins suppress FSH production, whereas, activins increase the follicular 
response to FSH. Proliferative phase lasts for the first 2 weeks of the 
menstrual cycle 
(19).
  
SECRETARY/LUTEAL PHASE:  
Ovulation occurs as a result of a midcycle peak in the production of LH and 
estradiol 
(18)
. This is followed by the production of progesterone, in the 
corpus luteum, by the granulosa cells. Progesterone in turn causes secretory  
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changes in the endometrium. During secretary phase, estrogen production 
persists at a lower level 
(17)
.  
MENSTRUAL PHASE: 
When fertilization fails to occur, the corpus luteum regresses and the highly 
vascular predecidualized endometrium undergoes disintegration and is shed 
over a period of five days. By the end of the menstrual phase, only the 
stratum basalis remains. As the next cycle begins, the epithelium from the 
gland crypts proliferate and the stromal integrity is regained 
(17)
.   
The gestational period is characterized by an increased production of 
progesterone which sustains the pregnancy 
(20)
.  
Around the fifth decade of life, the hormonal secretion begins to wane and 
results again in irregularity of the cycle lengths. Finally, as there are no 
more maturing follicles in the ovary, ovulation stops and so does the 
menstrual cycle 
(21)
.  
HISTOLOGY OF THE CERVIX 
The two portions of the cervix namely, the ectocervix and the endocervix 
are lined by different epithelia. The ectocervix is lined by a stratified 
squamous epithelium which is of a non-keratinized type. In the reproductive  
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years, this epithelium is composed of three layers- the basal/parabasal, the 
intermediate and the superficial. There is also an increase in accumulation 
of glycogen in the more superficial cells. The cervix at birth may show all 
three layers and even glycogenation of the squamous cells, due to the 
maternal hormonal effects.  
After menopause, the epithelium only shows the basal/parabasal layer and 
there is also an absence of glycogen within the cytoplasm of these cells. 
There is also an increase in nuclear:cytoplasmic ratio, which may be 
confused with a cervical intraepithelial neoplasm 
(22)
.  
The lining of the endocervix is composed of mucin secreting glandular cells 
with basally placed nuclei, arranged in a single layer. At birth, the 
endocervical epithelium is often seen on the ectocervix, but it soon reverts 
to its position at the external os. After puberty, this layer may extend into a 
portion of the anatomical ectocervix as well, in the form of “erosions” due 
to swelling of the cervix.  
The transformation zone is situated between the endocervical glandular 
epithelium and the squamous epithelium. In the foci of “erosions”, the 
glandular epithelium gets replaced by metaplastic squamous cells, altering 
the original squamo-columnar junction. The transformation zone begins to  
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get pulled up again in the late reproductive years and by the time menopause 
occurs, the squamo-columnar junction is found well within the endocervical 
canal. 
During pregnancy, the endocervical epithelium shows proliferation to 
increase the production of mucin.  
The cervical stroma is vascular and is composed predominantly of fibrous 
tissue with a few smooth muscle fibers running in between 
(9)
.  
HISTOLOGY OF THE UTERUS 
Histologically, the uterus shows three layers- the innermost endometrium, 
the myometrium and the serosa.  
THE ENDOMETRIUM: 
The endometrium is composed of glands lined by columnar epithelium 
(which varies in appearance in accordance with the phase of the menstrual 
cycle) and stroma which is composed of elongated endometrial stromal 
cells, lymphoid infiltrate, a reticulin framework and vascular elements. 
 At birth, the endometrium might be proliferative or even weakly secretory 
for a transient period due to the maternal estrogen influence. 
 
Review of literature 
 
16 
 
 
Histopathologic phases of the menstrual cycle: 
Menstrual phase 
Early proliferative and proliferative phase 
Day-16 endometrium  
Secretory phase - vacuolated, exhaustive and predecidual 
(17)
.  
Menstrual phase endometrium: 
In this phase there is diffuse breakdown of the endometrial stroma and the 
stratum functionalis is shed leading to the menstrual bleeding. Progesterone 
levels drop and matrix metalloproteinases such as gelatinase, collagenase, 
stomolysins etc., are released along with clotting factor activation followed 
by fibrinolysis 
(23)
.  
The earliest morphologic change that occurs is predecidual condensation 
into cords and groups separated by blood and inflammatory cells. Secretory 
exhausted glands are seen, which may be large and irregular with slight 
nuclear stratification to delicate, thin, single layered epithelial strands. The 
coordinated collapse of the functionalis with necrotic predecidua and sheets 
of neutrophils is called “scheduled breakdown”. An ovulatory cycle can be  
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most often diagnosed in the presence of predecidualised stroma and 
exhausted glands 
(24)
.  
When corpus luteum persists, irregular shedding occurs in which case the 
menstrual phase endometrium shows features of late secretory phase, like 
predecidualisation, along with late proliferatory phase changes like star 
shaped glands. Membranous dysmenorrhoea is a painful condition where 
the endometrium is shed in the form of a cast of the uterine corpus 
(17)
.  
Early proliferative and proliferative phase: 
In this phase, the glands appear tubular; the nuclei show pseudostratification 
and increased mitosis. Nuclear chromatin may appear coarse and the 
increased mitosis may give rise to a suspicion of malignancy. The nuclear 
size is regular and the glands are rounded with minimal irregularity and thus 
it is easily distinguished from malignant glands.  
Just before ovulation, edema develops in the stroma and the glands become 
tortuous. Confusion with secretory phase may occur when there is 
prominent spindling of cells, but there are no spiral arterioles. Also presence 
of „secretions‟ in glandular lumina does not indicate secretory phase when 
other changes are not present 
(17)
.  
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Day 16:  
Subnuclear vacuoles start appearing and mitotic rate is decreased. Other 
findings are that of a proliferative phase endometrium 
(24)
.  
Vacuole phase: 17-19 days 
Vacuoles are present uniformly in all glands and no mitosis is seen. If 
mitosis is seen with the above findings, a diagnosis of an ovulatory cycle 
cannot be made. In day 17 endometrium, vacuoles are subnuclear, pushing 
up the nuclei. In day 18, vacuoles move towards the lumen & secretary 
material starts appearing in the lumen. In day 19, the nuclei become basal 
again and the glands have a secretory exhausted appearance 
(17)
.  
Exhaustive phase: 20-22 days 
Secretory exhaustion is seen. This is followed by edema which increases 
and peaks by day 22 with prominence of spiral arterioles 
(17)
.  
Predecidual phase: 23-28 days  
Spiral arterioles are surrounded by predecidualized stroma i.e spindled cells 
occurring in a spiral aggregate around vessels. The stroma below the 
epithelium gets predecidualized next. Then there is confluence of  
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predecidua below the epithelium and between glands. Finally stromal 
granulocytes appear and become prominent 
(17)
.  
Arias-Stella reaction 
Arias-Stella first reported this endometrial epithelial change to occur as a 
result of chorionic hormonal stimulation. He emphasized on the fact that, 
this reaction can be diagnosed only in the presence of nuclear enlargement 
and not just cellular enlargement which can occur in a hypersecretory 
endometrium. The enlarged nuclei may be vesicular, hyperchromatic or 
even pyknotic looking, with irregularity of the nuclear membrane. Other 
changes that can be seen are chromatin clearing and nuclear 
pseudoinclusions. Because of these nuclear changes, this condition was 
thought to be an early malignancy before his report was published. This 
change is most often patchy and may be seen in uterine and extrauterine 
pregnancies, trophoblastic tumors and in post-abortion or post-partum uteri 
(20)
.  
The atrophic endometrium 
After menopause, the lining epithelium of the endometrium becomes 
flattened to cuboidal with loss of cilia. The glands may become cystically  
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dilated. The stroma shows spindle cells which do not undergo 
predecidualization 
(25)
.  
THE MYOMETRIUM: 
The uterine myometrium has an inner circular layer which extends to 
surround the tubal lumina and the cervical canal. The middle layer is 
composed of highly vascularized, interdigitating bundles of muscle fibers. 
The outermost layer is composed of longitudinal muscle bundles. During 
pregnancy the uterus increases in size owing to the hypertrophy as well as 
hyperplasia of the uterine muscle fibers. There is also an increase in the 
extracellular matrix and the vasculature. Post pregnancy, the uterus deceases 
in size owing to a decrease in size of the individual myocytes 
(9)
. 
DISEASES OF THE CERVIX: AN OVERVIEW 
 Metaplasias: Squamous, tubal, tuboendometrioid and transitional cell 
 Inflammatory conditions: Non infectious cervicitis- may result from 
erosion, iatrogenic injury- biopsy or conization or radiation. 
 Infections – Cervicitis: The commonest infections are those caused by 
Candida species, Trichomonas vaginalis, Neisseria gonorrhoeae, 
Gardnerella vaginalis and Herpes simplex virus (HSV). Other organisms 
causing infections are, Chlamydia trachomatis, Treponema pallidum,  
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 Mycobacterium tuberculosis, Actinomyces, Human papilloma virus 
(HPV), Cytomegalovirus (CMV) and Schistosoma hematobium.These 
conditions can cause reactive atypia and/or hyperkeratosis and 
parakeratosis. 
 Cervicovaginitis emphysematosa: This condition is characterized by 
multiple subepithelial cysts which are filled with gases including carbon 
monoxide. These spaces are not lined by any epithelium and do not seem 
to be caused by any gas forming bacteria. 
 Pseudoneoplastic conditions: Microglandular endocervical hyperplasia, 
diffuse laminar endocervical glandular hyperplasia, lobular endocervical 
glandular hyperplasia, endocervicosis, endometriosis, mesonephric 
hyperplasia and remnants, decidual pseudopolyps, inflammatory 
pseudotumor and mullerian papilloma. 
 Benign neoplasms: Endocervical and mesodermal stromal polyps, 
leiomyoma, adenomyoma, papillary adenofibroma, placental site 
trophoblastic nodule, hemangiomas, neurofibromas and 
ganglioneuromas, nevi and cysts such as nabothian cyst, inclusion cyst 
and tunnel clusters. 
 Precancerous conditions: cervical intraepithelial neoplasia- squamous 
and glandular. 
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 Malignant tumors: 
i) From the squamous epithelium- squamous cell, verrucous, warty, 
transitional and lymphoepithelioma-like carcinomas. 
ii) From the glandular epithelium- adenocarcinoma-NOS, 
villoglandular, clear cell, serous and mesonephric 
adenocarcinomas. 
iii) Others- adenosquamous carcinoma, glassy cell carcinoma, 
neuroendocrine tumors and salivary gland type malignancies- 
adenoid cystic, mucoepidermoid and adenoid basal carcinomas. 
iv) Mixed epithelial and mesenchymal tumors and secondaries (26). 
DISEASES OF THE UTERUS – AN OVERVIEW 
 Inflammations: These could be non infectious and infectious. 
Infectious causes include Chlamydia, Mycoplasma, Actinomyces, 
CMV, HSV, fungi and parasites. Non infectious causes include 
ligneous endometritis, malakoplakia, lymphoma-like lesions, 
dysfunctional uterine bleeding, epithelial metaplasias (squamous, 
tubal, mucinous, clear cell, hobnail, oncocytic and papillary 
syncitial), mesenchymal metaplasias (smooth muscle, glial, adipose, 
cartillagenous and osseous), extramedullary hematopoiesis,  
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Asherman‟s syndrome, effects of IUCD, emphysemoatous 
endometritis, post-operative spindle cell nodule etc. 
 Benign neoplasms: Endometrial polyps, atypical polypoid 
adenomyoma, adenofibroma etc. 
 Precancerous conditions: Endometrial hyperplasias- simple 
hyperplasia without atypia, simple hyperplasia with atypia,  complex 
hyperplasia without atypia, complex hyperplasia with atypia, 
hyperplasias with metaplasia (squamous, tubal, secretory, hobnail, 
mucinous and mixed cellular) and endometrial intra-epithelial 
carcinoma. 
 Cancers: 
i) Endometrioid adenocarcinomas, non-endometrioid 
adenocarcinomas, carcinosarcomas, germ cell tumors and 
metastatic tumors. 
ii) Mesenchymal tumors: Leiomyoma, diffuse leiomyomatosis, 
dissecting leiomyoma, intravenous leiomyoma, benign 
metastasizing leiomyoma, peritoneal (parasitic) leiomyoma, 
leiomyosarcoma, smooth muscle tumor of uncertain malignant 
potential (STUMP), perivascular epithelioid cell tumor, stromal 
tumors- benign and malignant, rhabdomyosarcoma, alveolar soft  
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iii) part sarcoma, adenomatoid tumor and primitive neuroectodermal 
tumor  
(26)
. 
THE WHO CLASSIFICATION OF ENDOMETRIAL CARCINOMAS: 
1. Endometrioid adenocarcinomas:  
i. With squamous differentiation 
ii. Villoglandular variant 
iii. Secretory variant 
iv. Ciliated cell variant 
2. Non endometrioid adenocarcinomas-  
i. Mucinous 
ii. Serous 
iii. Clear cell 
iv. Mixed cell 
v. Squamous cell 
vi. Transitional cell 
vii. Small cell 
viii. Undifferentiated (27).  
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ENDOMETRIAL CARCINOMA 
INTRODUCTION: 
About 3.2 lakh cases of cancer of uterus were reported in the year 2012, 
globally. The incidence of the cancer of the corpus uteri among women 
(globally) is 4.8%. In India, the incidence is only 2.3% and accounted for 
1.5% of cancer related mortality
 (1)
.  
Carcinomas of the endometrium are much more common than malignant 
mesenchymal neoplasms of the uterine corpus. The most common histologic 
type is the endometrioid adenocarcinoma (80%).The non endometrioid 
carcinomas comprise about 20% 
(28)
. Serous (5-10%) and clear cell (1-5%) 
are more frequent than the other non endometrioid carcinomas 
(27)
.  
CLINICAL FEATURES: 
Endometrial carcinomas are most common in the postmenopausal age group 
with a median age of 63 years. Less than one percent cases occur below the 
age of 40 years 
(2)
. Most cancers occurring in this younger age population 
are endometrioid adenocarcinomas of a better differentiation and present at 
an earlier stage compared to those occurring in postmenopausal women 
(28)
. 
Occasional cases have been diagnosed in pregnant women.  
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The commonest symptom is abnormal vaginal discharge most commonly 
abnormal vaginal bleeding, with a few cases presenting with leucorrhoea. In 
advanced cases with invasion, pelvic pain, pressure symptoms and 
metastasis related symptoms are seen. 
GROSS PATHOLOGY: 
Grossly, the tumor might be single, multiple or diffusely involving the 
endometrium. Most commonly, it appears as a broad based polypoidal mass 
with an irregular surface. Diffuse infiltration causes a bulky uterus. Minimal 
deviation invasion is the term used, when a very deep myometrial invasion 
has occurred without significant increase in size of the uterus. Younger 
patients have lesions more towards the lower uterine segment 
(28)
.  
HISTOPATHOLOGY: 
Endometrioid Adenocarcinoma: 
The tumor is composed of glands arranged in a complex cribriform pattern 
often with maze like interconnected lumina, solid areas and villoglandular 
pattern. The cells look similar to proliferative phase cells and show 
multilayering. The cells are larger than those seen in normal endometrium 
with rounded nuclei, clumped chromatin and often show prominent nucleoli. 
There may be small foci showing squamous, mucinous, tubal or other cell  
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types. Mitotic figure numbers vary with differentiation of the tumor. 
Stromal invasion within endometrium does not often provoke desmoplastic 
reaction, whereas spread into the muscle is often surrounded by a 
desmoplastic reaction of the stroma. Stroma may show some foamy cells. 
The criteria to diagnose malignancy include: 
1) Cribriform glands 
2) Solid areas 
3) Interconnected lumen 
4) Irregular glands 
Variants: 
i) With squamous differentiation: Squamous component is present to 
some extent in one fourth of endometrioid carcinomas. They are 
both neoplastic and metaplastic. When the squamous component is 
well differentiated, it is called adenoacanthoma. When poorly 
differentiated it is known as adenosquamous carcinoma. The 
former has a better prognosis. 
ii) Secretory cell carcinoma: It is an uncommon variant where the 
neoplastic glands show secretory changes, especially supranuclear 
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iii)  and/or subnuclear vacuoles. The changes may be progestin 
induced or it may be an intrinsic feature of the malignant cells. 
Sheets of cells with clear cytoplasm but not with significant atypia 
as seen in clear cell carcinoma may also be seen. The prognosis is 
good. 
iv) Ciliated cell carcinoma:  It is a rare variant. Occasional ciliated 
cells may be seen in most cases. If more than 75% cells have cilia, 
a diagnosis of ciliated cell carcinoma can be made. There also 
needs to be invasion for it to be differentiated from endometrial 
intraepithelial neoplasia. It has a good prognosis.  
v) Villoglandular variant: This has, long, slender papillae with 
cytological features of grade I endometrioid adenocarcinoma. 
Psammoma bodies, usually seen in serous carcinomas, may be 
seen in these tumors as well. The prognosis is excellent.   
Differentiating well differentiated endometrioid carcinoma from complex 
hyperplasia with atypia:  
Histologically, a complex cribriform glandular pattern in more than 30% of 
the biopsy tissue or marked nuclear atypia with pleomorphism and 
prominent nucleoli, are features more indicative of malignancy.  
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Myoinfiltration seen in hysterectomy specimens is the only conclusive 
evidence of malignancy. Genetically, PTEN and/or P53 mutation and a 
clonal expansion in tumor cell are signs of malignancy.  
Mucinous Adenocarcinomas: 
This accounts for a small percentage of endometrial carcinomas. It is often 
seen associated with an endometrioid component. It is more common in 
patients who have received Tamoxifen treatment or exogenous progestins. 
Presence of intracytoplasmic mucin may be seen in some of the cells in 
endometrioid adenocarcinoma. When more than half of the cells show this 
feature, the tumor is classified as mucinous adenocarcinoma. In biopsy 
specimens, they look a lot like endocervical fragments, but the delicate 
stroma, microglandular component and the alternation with non- mucinous 
endometrioid type fragments is often diagnostic.  The prognosis is usually 
good.  
Serous Carcinoma: 
They are aggressive type tumors with an older age of incidence than 
endometrioid type carcinomas. There is often no history of exposure to 
excessive estrogens, whether intrinsic or extrinsic and the women are mostly 
parous with normal serum estrogen levels. Endometrial hyperplasias or  
Review of literature 
 
30 
 
 
intraepithelial neoplasia have not been associated with this tumor, but serous 
intraepithelial carcinoma and endometrial glandular dysplasia have been 
identified as its precursor lesions. These tumors show complex, branching 
papillae with thick fibrovascular cores. Tufting of lining cells may be seen. 
There may also be glandular and solid areas. The lining cells are usually 
polygonal with marked pleomorphism, high N:C ratio and macro nucleoli. 
Tumor giant cells can be seen. Exfoliative cells with hob nailing are 
common. The prognosis is very poor.    
Squamous Cell Carcinoma: 
They are rare and occur at an older age group compared to other 
endometrial carcinomas. Icthyosis uteri, a condition in which there is 
extensive squamous metaplasia of the endometrium, is considered to be its 
precursor. It resembles squamous cell carcinomas in other organs and has 
little or no adenocarcinomatous elements. The prognosis is extremely poor 
with a median survival of only 9 months.   
Clear Cell Adenocarcinoma: 
A small percentage of endometrial carcinomas have this morphology. They 
occur at an older age than the endometrioid adenocarcinomas. The cells may 
be arranged in a papillary, solid, glandular or tubular-cystic pattern. Most of  
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the cells are seen to have a clear cytoplasm. Mitosis is frequently noted. 
Some of the cells have scant cytoplasm and large nuclei protruding into the 
lumen in a hobnail appearance. Prognosis is poor. 
Mixed Carcinoma: 
The term mixed carcinoma can be used when the individual components 
exceed 10% of the tumor volume. 
Undifferentiated Carcinoma: 
These tumors can be identified to be of epithelial origin, but further sub-
classification cannot be done. The cells may be large, anaplastic and form 
vague glandular pattern, or they may be of a small cell type 
(2)
.  
Transitional Cell Carcinoma: 
It usually shows papillary arrangement of cells. Often there is an associated 
second tumor type which may be endometrioid, clear cell or serous. This 
tumor may show koilocytes which are associated with HPV infection 
(27)
.  
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TECHNIQUES TO OBTAIN AN ENDOMETRIAL SAMPLE FOR 
PATHOLOGICAL STUDY: 
1. DILATATION AND CURETTAGE 
Endometrial samples can be obtained by dilatation and curettage, but it is a 
procedure with much discomfort to the patient. It may still miss 5-10% of 
endometrial lesions. 
2. ENDOMETRIAL BIOPSY 
Limited biopsies can be obtained without dilatation, as an office procedure, 
with much less discomfort to the patient. When guided by hysteroscopy, a 
representative biopsy can easily be obtained. 
3. VEBRA ASPIRATOR BIOPSY 
This method uses a suction curettage device called the Vebra aspirator, 
which is made of steel. It is preferred for women of reproductive age group 
as it often provides inadequate samples in postmenopausal women. 
4. PIPELLE BIOPSY 
The device used for this biopsy is widely used in the United States and in 
Europe and is performed as an office procedure. Pipelle is also a suction 
curettage device, but is made of plastic 
(2)
.   
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5. ENDOMETRIAL CYTOLOGY 
Sample can be obtained using a Tao brush, which is an ensheathed brush. 
This can be introduced up to the uterine fundus. The sheath is then removed. 
The exposed bristles will collect the endometrial cells when rotated in one 
direction only for four to five times. The sheath is then replaced to cover the 
bristles to avoid contamination with cervical or vaginal material, while 
taking the brush out. This brush is then cut off into a container with liquid 
fixative and processed as for cervical liquid based cytology. The advantage 
with this procedure is that it is relatively painless 
(29)
.  
6. HYSTEROSCOPIC BIOPSY 
This allows for a targeted biopsy of the hysteroscopically abnormal region 
of the endometrium 
(2)
. 
RISK FACTORS FOR ENDOMETRIAL CARCINOMA 
Excessive estrogen stimulation is the most common risk factor and it may 
be exogenous or endogenous. 
Exogenous estrogen stimulation is seen with Tamoxifen, administered to 
breast cancer patients in whom it acts as a competitive inhibitor of estrogens 
with an antagonistic effect. In the endometrium though, it seems to have a  
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weak agonistic effect, especially in postmenopausal women. The increase in 
risk is 2-3 times and the tumors are more often low grade 
(30)
. 
Endogenous estrogen exposure may be physiological or pathological.  
Physiological causes include, early age at menarche, late menopause and 
low or nulliparity. 
Pathological causes include infertility, anovulatory cycles and estrogen 
producing ovarian conditions like granulosa cell tumors, thecomas, 
polycystic ovarian disease and hyperthecosis 
(2)
.  
Other associated risk factors are obesity, diabetes, gonadal dysgenesis, 
Stein-Leventhal syndrome and Hereditary Non Polyposis Colonic Cancer  
(HNPCC) syndrome 
(22)
.  
Cigarette smoking has been shown to have a protective effect in post 
menopausal women who are current smokers 
(31)
. Conversely, smoking has 
been associated with a more advanced stage at presentation 
(32)
.   
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FACTORS THAT INFLUENCE THE PROGNOSIS IN 
ENDOMETRIAL CARCINOMA 
Prognostic factors help in establishing the probable disease outcome for a 
patient and also to determine the need for adjuvant therapy. A useful 
prognosticator ought to: 
1) Help identify two or more sets of patients on the basis of disease free 
survival and recurrence. 
2) Both univariate and multivariate analysis must show it to have a 
statistical significance as a prognosticator. 
3) The population studied must be large and representative. 
4) It should be reproducible. 
5) Multiple studies must have proved its significance.  
The important prognostic factors for endometrial carcinomas include: 
1) FIGO stage  
2) Histologic grade 
3) Cell type 
4) Myometrial invasion 
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5) Vascular and lymphatic invasion 
6) Peritoneal cytology 
7) Ploidy 
8) Steroid receptors 
9)  Bcl2 and proliferation markers 
10) Angiogenesis and VEGF 
1. FIGO STAGING OF ENDOMETRIAL CARCINOMA: 
The International Federation of Gynecology and Obstetrics (FIGO) adopted 
its first rules for the staging of uterine cancer in 1958. The UICC 
(International Union Against Cancer) and the American Joint Commission 
on Cancer (AJCC) published their own staging systems in 1966 and 1976 
respectively. FIGO revised its staging system subsequently and the 1988 
revision was in vogue till September 2008, when the revised proposal of 
FIGO staging for endometrial cancer was approved by the FIGO executive 
board. What follows below (Table 1) is the Revised FIGO staging published 
in 2009 in the International Journal of Gynecology and Obstetrics, which is 
the official mouthpiece of FIGO
(33)
. Multivariate studies have proved it to be 
the single strongest predictor of outcome for endometrial carcinomas 
(22)
.  
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Table 1: Revised FIGO staging of endometrial carcinoma 
STAGE CHARACTERISTICS 
I A 
Tumor involving the endometrium with no or <1/2 of 
myometrium involved 
I B 
Tumor involving the endometrium with >1/2 of myometrium 
involved 
II Cervical stromal involvement 
III A Serosa of the uterus or adnexae involved 
III B Vaginal or parametrial involvement 
III C 
Metastasis to pelvic or para-aortic nodes 
C1- pelvic nodes involved  
C2- para-aortic nodes involved with/without pelvic node 
involvement 
IV A Invasion of bladder and/or bowel mucosa 
IV B 
Distant metastasis, including intra-abdominal and/or inguinal 
nodes 
 
Endometrioid adenocarcinomas usually present at stage I, whereas serous 
carcinomas present at stage III or IV in 72% of cases 
(2)
. 
2.  HISTOLOGIC GRADING: 
There are two systems of histological grading, one based on the tumor 
architecture (Table 2) and the other based on the nuclear morphology (Table 
3). 
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Table 2: Grading of endometrial carcinoma based on tumor 
architecture: 
GRADE CHARACTERISTICS 
Grade I </= 5% tumor growth is in solid sheets 
Grade II 6-50% tumor growth is in solid sheets 
Grade III >50% tumor growth is in solid sheets 
 
Architectural grading does not take into account areas of squamous 
differentiation 
(22)
. The most common architectural grade of endometrioid 
adenocarcinoma is grade I (50%). Grade 3 cancers are often associated with 
an older age at presentation 
(28)
.  
Table 3: Grading of endometrial carcinoma based on nuclear features: 
 
GRADE CHARACTERISTICS 
Grade I 
Round to oval nuclei with evenly distributed chromatin 
and inconspicuous nucleoli  
Grade II 
Irregular oval nuclei with chromatin clumping and 
moderate sized nucleoli 
Grade III 
Large pleomorphic nuclei with coarse chromatin and 
large irregular nucleoli  
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When the nuclear grade is three, the architectural grade of grade I and II 
lesions is raised by one for endometrioid adenocarcinomas. Generally, while 
grading the non-endometrioid adenocarcinoma, only the nuclear grade is 
used except in mucinous carcinoma where architectural grading is preferred 
(22)
.  
3. CELL TYPE: 
Endometrioid carcinoma, its variants and mucinous adenocarcinoma have a 
good prognosis and are often classified as type I endometrial carcinoma. 
Whereas, serous adenocarcinoma, clear cell adenocarcinoma and squamous 
cell carcinoma have a poor prognosis and are clubbed under type II 
endometrial carcinoma 
(22)
.  
4. MYOMETRIAL INVASION: 
Myometrial invasion may be absent or present. If present, there may be 
invasion up to the inner half or the invasion may extend into the outer half. 
The prognosis worsens in proportion with the depth of invasion. 
Involvement of adenomyotic sites cannot be considered as myometrial 
invasion. There needs to be a desmoplastic reaction around the malignant 
glands to call it a true invasion 
(22)
. 
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5. VASCULAR AND LYMPHATIC INVASION:  
Invasion into vascular or lymphatic channels is diagnosed by the presence of 
nests of cells surrounded by flattened endothelial lining cells. The 
recurrence risk is higher when invasion is present. Lymphatic invasion in 
particular is an independent prognostic factor with poor survival and high 
recurrence rate 
(22)
.  
6. PERITONEAL CYTOLOGY: 
The only indicator of extra uterine spread in about 5-15% cases is the 
presence of positive peritoneal cytology. The recurrence rate was found to 
be 40% as compared to 10% in patients with a negative peritoneal cytology. 
It predicts an increase in disease related death 
(22)
. 
7. PLOIDY: 
Flow cytometry and static cytometry can help determine the ploidy of cells. 
In most endometrial carcinomas around two thirds of cells have been found 
to be diploid. Tumors with diploid cells as a majority have a better 
prognosis than those with more of aneuploid cells 
(22)
. 
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8. STEROID RECEPTOR STATUS: 
Estrogen and progesterone receptor positivity indicates a better 
differentiation of the tumor, better prognosis with less recurrence and better 
survival 
(22)
.  
9. PROLIFERATION MARKERS: 
The proliferation rate of cells within the tumor can be assessed by mitotic 
counts, S-phase fraction determination using flow cytometry and 
immunohistochemical staining for proliferating cell nuclear antigen. 
Increase in proliferation rate indicates a progressing tumor and so a poorer 
prognosis 
(22)
.  
10. APOPTOSIS MARKERS: 
Bcl2 expression has been found to increase from endometrial hyperplasias 
to poorly differentiated carcinomas. Decreased Bcl2 expression correlates 
with PR negative status, increased depth of invasion, increased FIGO stage, 
worse cell types, increased lymph node metastasis and tumor recurrence 
(22)
. 
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11. ANGIOGENESIS AND VEGF: 
Proliferation of capillaries is essential for continued tumor growth. VEGF 
expression is an independent prognostic factor for poor survival, poorer 
differentiation, increased stage and lymphatic invasion 
(22)
. 
 
ROLE OF IMMUNOMARKERS IN ENDOMETRIAL CARCINOMA 
IMMUNOMARKERS- A BRIEF HISTORY 
Albert H. Coons first developed immumomarkers for an 
immunofluorescence method for detection of specific antigens in frozen 
sections, in the year 1940 
(34)
.  Later, the horseradish peroxidase was used to 
label the antibodies, along with a color producing substrate, so that the 
immunomarkers can be used in light microscopic detection of antigens 
(35)
. 
The sensitivity of the procedure was further increased by making it a 
multistep process using avidin-biotin conjugate, biotin streptavidin method, 
amplification using substances like tyramide and polymer based labeling 
system 
(36)
. 
 Initially, the technique had application only with cryostat preparations, but 
in 1974, it was shown that it could be applied to paraffin-embedded tissues  
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as well, by Taylor and his collegues 
(37)
. In the year 1991, the antigen 
retrieval technique, which involves heating of paraffin sections, was 
developed to unmask antigens that have become altered by fixation in 
formalin. This enhanced the intensity of staining by the immunomarkers 
(38)
.  
 
IMMUNOHISTOCHEMISTRY (IHC) – BASIC CONCEPTS 
It is a technique based on the recognition of specific antigens by their 
antibodies, and by this interaction, these antigens can be located on their 
specific sites in the cells and tissues.  
An antigen, also known as an epitope, is a molecule which can stimulate the 
production of specific antibodies, and which possesses one or more sites for 
the binding of that antibody.  
An antibody is a protein substance with one or more of a basic unit called 
the monomer which is Y shaped. This monomer has a pair of light chains 
and a pair of heavy chains. The Fab portion- formed by the two light chains 
and portions of the two heavy chains- is the portion that binds with the 
antigen. The remainder of the heavy chain regions forms the Fc (fragment 
crystallizable) portion of the antibody. Monoclonal and polyclonal 
antibodies are being produced commercially. Polyclonal antibodies are  
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composed of a mixture of antibodies, which can detect several epitopes on a 
single antigen. These are produced using live animals and can be used on 
denatured proteins as well as antigens that have lost one or a few epitopes. 
Monoclonal antibodies, on the other hand, can detect only a single epitope  
on an antigen. Though it is highly specific, it is sensitive to loss of a single 
epitope on the antigen. These are produced from cell cultures 
(39)
.  
Advantages of immunohistochemistry: 
 It can be done on formalin fixed paraffin embedded specimens.  
 It can be done on stored, archival material 
 It is highly sensitive and specific 
 When used on frozen section, an easily reproducible 
immunofluorescence technique which is simple and rapid can be 
used. 
 When used on paraffin blocks, peroxidase in combination with a 
diaminobenzidine chromogen allows for long term storage of slides 
without fading of the stain 
 There is no need for a high cost equipment like a fluorescence 
microscope
(39)
. 
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IMMUNOHISTOCHEMISTRY –GENERAL APPLICATIONS 
The main application of IHC is in the typing of the cellular differentiation of 
neoplasms, which may in many instances be challenging on light 
microscopy. Earlier, electron microscopy was used for this purpose, but 
nowadays, IHC has replaced this costly and tedious procedure. 
This has been especially useful in the workup of: 
 Anaplastic tumors 
 Small round cell tumors 
 Soft tissue tumors 
 Lymphoma  
 Metastatic tumors with an unknown primary 
In some instances it has also been used to differentiate a reactive process 
from a neoplasm- e.g. differentiation of a low grade astrocytoma from a 
reactive gliosis. 
They are also used as prognostic indicators- e.g. proliferation markers like 
MIB-1 can demonstrate the aggressiveness of tumors and gene amplification 
of oncogenes like HER2/neu indicates a bad prognosis. 
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Some markers like the estrogen and progesterone receptors are used to 
predict the responsiveness of a tumor to therapy. 
Detection of infectious viruses such as HSV, CMV, oncogenic viruses such 
as HPV, HSV, Estein Barr virus (EBV) and other infectious agents such as 
Mycobacteria, Cryptococcus etc., has also been made using 
immunomarkers. 
The diagnosis of some non-neoplastic diseases of the brain and the muscle 
also requires immunomarkers 
(39)
. 
IMMUNOMARKERS THAT HAVE BEEN STUDIED IN 
ENDOMETRIAL CARCINOMA: 
Advanced type I and type II cancers have a poor response to therapy and a 
worse prognosis. These are the tumors that may with the help of novel 
therapeutic targets be treated more adequately through individualized 
treatment.  
Changes in gene expressions induced by mutations can be studied using 
IHC and thus newer therapeutic targets can be identified. Many are 
underway in which various targeted therapies are being used as 
monotherapy or in combination with chemotherapy and radiotherapy. 
Majority of these studies use receptor tyrosine kinase (RTK) inhibitors,  
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mammalian Target of Rapamycin (mTOR) inhibitor and estrogen inhibitors 
like Selective Estrogen Receptor Modulators (SERMs) and aromatase 
inhibitors. The remaining trials use agents like cyclooxygenase-2 (COX-2)  
inhibitors, cell cycle inhibitors, gonadotropin releasing hormone (GnRH) 
analogues, folic acid analogs, histone deacetylase (HDAC) inhibitors, the  
monoclonal antibody RAV12, CALAA-01, protein kinase-C inhibitors and  
mitogen activated protein kinase (MAPK) inhibitors.  
ErbB receptor family and vascular endothelial growth factor (VEGF) 
receptor family are the RTK inhibitors being most widely studied. These 
agents target tumour cells or the tumour environment including stromal 
cells, endothelial cells, endothelial precursor cells, pericytes, and immune 
cells. 
Tumor growth and progression depends very much on angiogenesis. VEGF 
is an endothelial cell-specific growth factor. It is indeed the principal 
regulator of angiogenesis in most organs, under normal as well as 
pathological conditions. It promotes the growth and the propensity to 
metastasize in several cancers, including endometrial cancer. 
ErbB receptors and their ligands promote tumourigenesis by stimulating and 
accelerating tumour growth, survival, metastasis, invasion, angiogenesis and 
drug resistance.  
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HER-2neu expression has been found to be an independent prognostic 
factor in endometrial cancer. It is one of the critical oncogenes in high-grade 
and poor prognostic endometrial cancers. Inhibition of this receptor in poor 
prognostic endometrial cancer may be of some potential benefit. 
The mitogen activated protein kinase (MAPK) pathway induces growth 
factors to promote survival and proliferation of tumor cells as well as 
normal cells. 
Endometrial tumours show alterations in expression and activity of protein 
kinase C (PKC) isoforms, which seem to co-regulate apoptotic cell death. 
CALAA-01 a small interfering RNA (siRNA), inhibits tumour growth by 
means of RNA interference thus reducing expression of R2, the M2 subunit 
of ribonucleotide reductase. 
Uterine papillary serous cancers have been found to often overexpress 
claudin-3 and claudin-4 membrane proteins, which have been reported to be 
implicated in tumour invasion and tumor metastatic potential. 
COX-2 
BASIC INFORMATION ON COX-2: 
Cyclooxygenase (COX) is an enzyme which catalyzes the conversion of 
arachidonic acid to prostaglandin G2. This is the rate limiting step in the 
synthesis of prostaglandins. Prostaglandin G2 is then converted to  
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prostaglandin H2 from which prostaglandins D2, E2, F2, I2 and 
thromboxane A2 are derived. There are two isoforms of cyclooxygenase – 
COX-1 and COX-2. The COX-1 isoform, is the enzyme involved in this 
process in normal conditions and it is involved in protection of gastric 
mucosal cells, platelet aggregation and renal vasodilatation. COX-2 is an 
inducible isoform that is expressed in the presence of cytokines in 
inflammatory conditions. It has also been found to be stimulated by 
oncogenes, tumor promoters and growth factors (Figure 1).  
Figure 1: The arachidonic acid pathway 
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INVOLVEMENT OF COX-2 IN TUMORIGENESIS: 
COX-2 has been shown to be constitutively expressed in various malignant 
tumors. It is considered to promote tumorigenesis by promoting 
angiogenesis, inhibiting apoptosis, inducing cell proliferation, enhancing the 
metastatic potential and by suppressing host immunity (Figure 2). 
 
Figure 2: COX-2 in tumorigenesis and tumor progression 
 
Angiogenesis: 
Prostaglandin E2 induces the production of VEGF, matrix 
metalloproteinases and Bcl-2, all of which are involved in promoting 
endothelial cell proliferation. Prostacyclin induces the proliferating  
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endothelial cells to form new vascular sprouts. The endothelial cells produce 
proteases which facilitate vascular sprouting. Thromboxane A2 promotes 
the formation of capillary tubes by the migration of the proliferating 
endothelial cells towards the tumor site. Bcl-2 imparts survival advantage to 
the newly formed vessels (Figure 3). 
 
 
Figure 3: COX-2 in angiogenesis 
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Prevention of apoptosis: 
COX-2 overexpression causes increased production of Bcl-2 which inhibits 
apoptosis. This increase in Bcl-2 production is due both to the reduction in 
the concentration of arachidonic acid and the increased production of 
prostaglandin E2 which activates the EP (Prostaglandin E2) receptors. The 
activation of EP receptors also leads to down-regulation of nitric oxide 
signaling which can further prevent apoptosis. The concentration of 
ceramide, an apoptosis inducer, within cells parallels that of COX-2.  
Induction of cellular proliferation: 
PGE2 acts via the EP receptors which activate phosphatidylinositol 3 –
kinase / protein kinase B pathway (PI3K/Akt) which promotes cellular 
proliferation. 
Metastatic potential: 
COX-2 decreases the adhesion of cells with one another by decreasing the 
expression of E-cadherin. These dyscohesive cells then acquire motility via 
the up-regulation of the PI3K/Akt pathway. The invasion of vessel wall by 
these migrating cells is facilitated by membrane metalloproteinases. Both 
cell migration as well as invasion is dependent upon the presence of the cell 
surface receptor CD44 
(40)
 (Figure 4). 
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Figure 4: COX-2 increases metastatic potential 
 
 
 
Suppression of the host immune system: 
Prostaglandin E2 inhibits the functions of antigen presenting dendritic cells. 
It also inhibits T cell activity by preventing the production of interleukin-2 
(IL-2) and  interferon-  (INF  as well as by decreasing the IL-2 receptor 
expression. The fact that COX-2 mediates immune suppression in tumor 
tissues has been validated by DeLong et al. who demonstrated the 
reinstatement of the anti-tumor response of the host immune system by the 
administration of COX-2 inhibitors 
(41)
. 
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EXPRESSION OF COX-2 IN VARIOUS TYPES OF NEOPLASMS: 
The reduced incidence of colonic cancers in non-steroidal anti-inflammatory 
drug (NSAID) users has been the stimulus for scientists to study COX-2 
expression in tumors 
(42)
. 
Molecular studies performed at tissue level showed that, while COX-2 was 
either undetectable or expressed weakly in normal tissues harboring the 
cancer, it was overexpressed in cancer tissues. COX-2 is found to be 
overexpressed in many solid cancers such as head and neck tumors, 
esophagus, stomach, lung, breast, bladder, prostate and pancreas 
(43)
.  
The first major study in India was published in 2011 by scientists from the 
department of Virology, King Institute of Preventive Medicine and 
Research, Chennai, where they observed overexpression of COX-2 in breast 
and lung cancers 
(44)
. 
 In the same year, a study from the CSM Medical University, Lucknow 
showed that COX-2 was overexpressed in about 16% of squamous cell 
carcinomas of oral cavity and it was more common in larger tumors than 
small sized tumors 
(45)
. 
COX-2 overexpression is more common in invasive cervical squamous cell 
carcinoma and adenocarcinoma than in in-situ carcinoma 
(46)
. Up regulation 
of COX-2 in bladder cancer and its dependence on TLR-4 was observed by 
Priyadarshini et al 
(47)
. The most recent article published in 2014 by Soni  
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Kumari, Shashi Prakash Mishra, Rahul et al, showed that the incidence of 
COX-2 overexpression increased with the stage and with the presence of 
Helicobacter pylori in gastric cancer 
(48)
. Thus, many centers in India have 
reported overexpression of COX-2 in various cancers and most of the 
studies have shown that the expression increases with tumor stage and size. 
COX-2 IN ENDOMETRIAL CARCINOMAS: 
Although COX-2 is either weakly expressed or not expressed in most of the 
normal tissues in the body, it has been found to be expressed by the normal 
glandular epithelium of the endometrium 
(40)
.    
Studies of COX-2 expression in endometrial carcinomas started getting 
published in 2000 when Tong et al., found that COX-2 is overexpressed in 
endometrial carcinoma cells compared to normal endometrial cells 
(49)
.  
COX-2 expression was found to be up regulated in endometrial cancer, 
being localized to the neoplastic epithelial cells as well as the normal 
endothelial cells, which were used as an inbuilt control in the study by 
Sugimoto et al 
(50)
.  
Ferrandina et al in 2002 found a higher COX-2 positivity in endometrial 
carcinomas of stage II and above than in tumors presenting at stage I. There 
was also an increase in COX-2 positivity with worsening histological grades 
(P - 0.0049). Cases with deep myometrial invasion showed a significant 
correlation with COX-2 overexpression (P=0.0003). Also the P value  
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showed statistical significance for shorter disease free survival among the 
cases which overexpressed COX-2 (P= 0.028) 
(51)
.  
Lambropoulou et al in 2005 have found that COX-2 overexpression 
correlated significantly with the FIGO stage of the endometrial carcinomas 
(p=0.010). A positive correlation was also found with histological grade 
(p=0.019) and myometrial invasion (p=0.026). However, COX-2 
overexpression did not correlate with the histologic type of the tumor 
(p=0.164). There was however a significant correlation between COX-2 
overexpression and reduced survival rates (p=0.028). They thus suggest that 
COX-2 overexpression is an independent clinicopathological and prognostic 
factor in endometrial cancers  
(52)
.  
Ferrandina et al in 2005 and Orejuela et al in 2005 did not find any 
correlation between COX-2 positivity and any of the clinicopathological 
features 
(53, 7)
.  
Horn et al studied the expression of COX-2 in the more aggressive 
squamous cell carcinomas of the endometrium and found it to be 
overexpressed in all eight of their cases 
(8)
.  
Fowler et al in 2005 found that COX-2 expression correlated well with 
histologic grade (P < .026) and approached statistical significance for deep 
myometrial invasion (P < .055) 
(54)
.  
 
Review of literature 
 
57 
 
 
Li et al in 2006 found the overexpression of COX-2 in 64.7% of 
endometrial cancers but not in normal endometrium. They found that grade 
2 tumors overexpressed COX-2 at a higher frequency than grade 3 tumors at 
P < 0.05). They have therefore suggested that overexpression of COX-2 
may be involved in induction of VEGF expression, upregulation of 
angiogenesis, and enhancement of tumor growth 
(55)
.  
Nasir et al in 2007 have found a high COX-2 positivity rate in endometrial 
adenocarcinoma tissues (88%) as compared to endometrial hyperplasias and 
non neoplastic endometrium 
(6)
. These observations are  
similar to those reported in other studies as well 
(56)
, while some 
investigators have found comparable proportions of endometrial carcinomas 
(92%) and proliferative endometrium (86%) to express COX-2 
(57)
. 
Keser et al in 2010 did not find a statistically significant difference between 
subgroups of histological grade, myometrial invasion and COX–2 scores. In 
addition, they were not able to establish a statistically significant correlation 
between steroid receptor status and COX-2 expression at P <0.05 
(58)
.  
In another study by Cao JQ and team, COX–2 was not expressed by 
atrophic, proliferative and hyperplastic endometrium. There was a weak to 
moderate granular cytoplasmic expression in well-differentiated endometrial 
carcinoma. There was however a strong expression of COX-2 
(overexpression) in the more poorly differentiated tumors. According to the  
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authors, the overexpression of COX–2 in moderate to high grade 
endometrial carcinomas suggested that COX–2 was involved in tumor 
progression rather than tumor initiation 
(59)
.  
Erkanli et al. could not demonstrate any association between overexpression 
of COX–2 and prognostic factors like myometrial invasion, grade or stage 
in endometrial cancers 
(60)
. 
Jeon et al. reported that COX–2 immunoreactivity of normal endometrial 
glands and stroma was minimal, irrespective of menstrual phase. In contrast, 
tumor cells showed significant immunoreactivity for COX–2.  
Twenty-seven of the 152 specimens studied were COX–2 positive (17.8%). 
COX–2 overexpression was not associated with a statistically significant 
correlation with any of the clinicopathological parameters studied by the 
authors except for the menstrual status. They observed that post menopausal 
women overexpressed COX-2 more frequently than premenopausal     
women 
(61)
.  
In a study by Ohno et al. which consisted of 70 endometrial carcinoma 
cases, the expression of COX–2 was strong in 37 (53%) patients and weak 
in 33 (47%) patients. They found increasing COX-2 overexpression with 
worsening tumor stage and deep myometrial invasion but were not able to 
establish a statistically significant association 
(62)
.  
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In 2005, Hasegawa et al studied the effects of the selective COX-2 inhibitor, 
Etodolac on endometrial carcinoma cell line called TMG-L, which was 
found to overexpress COX-2. They demonstrated that Etodolac caused 
inhibition of cell proliferation in this cell line by arresting the cell cycle at 
G1 phase. The effect of the drug was found to be dose dependent. They 
hypothesized that this cell cycle arrest is brought about by an increase in the 
expression of p53 and P21WAF1 proteins caused by COX-2. The drug was 
also found to inhibit the production of basic-Fibroblast Growth Factor (b-
FGF) and the activity of the telomerase enzyme 
(63)
. Later in 2012, they 
followed up this study with another in which a group of 21 patients with 
endometrial carcinoma were administered Etodolac prior to surgery. COX-2 
overexpression was present in 16 and absent in 5 cases. They obtained the 
endometrial cytology samples after the treatment trial and studied the 
cellular features. They found a reduction in the mitotic index in all of the 
cases which had overexpressed COX-2. There was also a reduction in the 
nuclear atypia, anisokaryosis, hyperchromasia and nuclear/cytoplasmic ratio 
in some of these cases. Further, they did not find any alterations in the 
cytologic features, in cases that did not over express COX-2. They therefore 
concluded that, Etodolac, a selective COX-2 inhibitor, has antitumor effects 
on endometrial cancer tissue 
(64)
.  
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Scoring systems for COX-2 immunostaining: 
Literature that evolved on the detection of COX-2 in endometrial tissues and 
cancers showed that the expression was higher in cancers. This necessitated 
the need to define overexpression to differentiate from mere expression. 
Several scoring systems are in vogue whose common denominator is 
bringing out objectivity in reporting and to eliminate bias. The following is 
a review of the scoring systems used to define overexpression of COX-2. 
1. Fujiwaki, et al, in 2001, gave a score of 0-4 for the percentage of cells 
stained: 0 for none, 1 for 1-25%, 2 for 26-50%, 3 for 51-75%  
and 4 for 76-100% and a score of 0-3 for the staining intensity: 0 for 
none, 1 for week, 2 for moderate and 3 for intense. The intensity was 
compared with the staining intensity in smooth muscle cells which 
was given an arbitrary score of 2. As the staining intensities varied in 
different parts of the same tumor, the score of the intensity and 
percentage of cells stained, in the various parts of the tumor were 
multiplied and the products were summed up to give the final       
score 
(56)
.  
2. Jeon, et al, in 2004, used a simpler system. They used a median value 
of 5% as the cut off for defining COX-2 overexpression by the tumor 
cells 
(61)
. However, Ferrandina et al raised the median value to 26% in 
their study 
(53)
.  
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3. Fowler, et al, in 2005, gave a combined score for the staining 
intensity and the percentage of cells stained. A score of 3+ was given 
for strong cytoplasmic staining in >50% cells, 2+ for weak 
cytoplasmic staining in >50% cells, 1+ for strong or weak 
cytoplasmic staining in 50% - 10% of cells and 0 for staining of 
<10% of cell or no staining. A score of 2+ or 3+ was considered as 
overexpression 
(54)
.  
4. Orejuela et al, used only the percentage of cells stained for scoring 
the slides. Their scores were: 0 for no staining, 1 for staining in <10% 
of cells, 2 for staining in 10-50% of cells and 3 for staining in >50% 
of cells. Scores 2 and 3 were considered as overexpression 
(7)
. 
5. Li, et al, in 2006, used a similar system for scoring as Fujiwaki, et al, 
but instead of multiplying the scores for the staining intensity and the 
percentage of cells stained they summed up the scores and considered  
a final score of 3 or above to be indicative of COX-2 overexpression 
(55).
   
6. Erkanli, et al, in 2007, followed the same scoring system as Li, et al, 
but the cut off for overexpression was increased to a final score of 4 
or more 
(60)
.  
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7. Nasir, et al, in 2007, used a semi quantitative scoring system in which 
an intensity score of 0-3 (0- negative, 1+ - weak, 2+ - medium and   
3+ - strong) was given and the percentage of cells that have taken up 
the stain were identified and the final score was arrived at using the 
formula- (3 x % of cells staining 3+) + (2 x % of cells staining 2+) + 
(1 x % of cells staining 1+). They used the vascular endothelial cells 
and macrophages as the positive internal control 
(6)
.  
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Type of study: 
This is a retrospective study performed on all consecutive cases of 
endometrial carcinoma, reported on hysterectomy specimens from the year 
2007 to 2013, in the Department of Pathology of the PSG Institute of 
Medical Sciences and Research. 
Arriving at the study population: 
The histopathology registers of the years 2007 to 2013, maintained in the 
Department of Pathology were accessed to obtain the following set of 
information: 
1. The total number of biopsies received in the Department of Pathology 
of PSG Institute of Medical Sciences and Research during the study 
period. 
2. The number of biopsies that were reported as malignant.  
3. Among the malignancies, the total number of endometrial carcinomas 
reported.  
4. Of the total number of endometrial carcinomas, the list of cases for 
which the diagnosis was made on a resection specimen. This list was 
the study population. 
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Retrieving the study material: 
All the histopathology slides of the study population were retrieved. The 
slides of all these cases were reviewed, first by me and then by my guide. 
We identified the most representative slides containing a fair amount of the 
tumor material. As a thumb rule, we chose those slides, which had a 
minimum, well-preserved tumor area of 40% – 50% with necrotic tissue not 
exceeding 20% of the total tissue. This was done to prevent staining artifacts 
while performing immunohistochemical studies. The specific 
histopathology numbers of these slides were noted and the corresponding 
blocks were retrieved from the archives with the help of the histopathology 
support staff.  
Two slides were prepared from each of these blocks, one of which was 
stained with the hematoxylin and eosin stain and the other with the COX-2 
immunostain. 
Procedure of Hematoxylin and Eosin staining:  
This comprised four sequential processes. These were section cutting of the 
chosen paraffin blocks, deparaffinization, staining proper and mounting. 
Section cutting was performed on Leica semi-automated  
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microtome fitted with disposable cutting blades. Deparaffinization and 
staining was done in a fully automated robotic auto-stainer (Leica 
Autostainer XL) using a program, specific to H&E staining. Mounting was 
done manually.  
As a first step, 4-5 micron thin sections were cut and floated onto two slides. 
One of the slides was a frosted slide coated with egg albumin. This slide 
was for Hematoxylin and Eosin staining. The other slide was a frosted slide 
coated with poly-L-lysine for immunohistochemical study. The sections 
floated onto egg albumin coated frosted slides were air dried after which the 
slides were placed in the Leica Autostainer for deparaffinization and 
staining. The program schedule for these activities was as shown below: 
i. Heating in an oven for 6 minutes at 65oC to liquefy paraffin wax. 
ii. Two changes in 97% Xylene for 5 minutes each to remove molten 
wax. 
iii. Transfer of slides to a 1:1 mixture of xylene and alcohol for 30 
seconds. 
iv. Three changes in 99% alcohol for 30 seconds each, to remove 
Xylene. 
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v. One change in tap water for 30 seconds, to wash off excess alcohol. 
vi. Harry’s hematoxylin for 5 minutes, for nuclear staining. 
vii. One change in tap water for 1 minute, for bluing of the hematoxylin. 
viii. Removing the excess stain by differentiating in 1% acid alcohol for a 
period of 30 seconds, followed by a wash in tap water for 2 minutes 
(regressive staining). 
ix. Staining with 1% eosin for 2 minutes – cytoplasmic staining. 
x. Washing off the excess stain in tap water for 30 seconds. 
xi. The slides were then air-dried, cleared with Xylene and finally 
mounted using Distyrene Phthalate Xylene (DPX). 
Procedure of Immunohistochemistry (IHC) 
Immunohistochemistry staining was performed manually. The steps were: 
1. 4 to 5μm thickness sections were cut and floated on to poly- L- lysine 
coated slides.  
2. Incubation at 37oC for 12 hours during the day and then at 58oC for 
the next 12 hours.   
3. Deparaffinization was performed using two successive jars of xylene 
for 15 minutes each. 
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4. The xylene was then removed in two successive changes of absolute 
alcohol for 1 minute each. 
5. The sections were then treated for one minute each in 90% alcohol 
and 70% alcohol. 
6. Rehydration was carried out using tap water for 10 minutes. 
7. The slides were then rinsed in distilled water for 5 minutes. 
8. Antigen retrieval was done by pressure-cooking the sections in citrate 
buffer at a pH of 6.0 for 10 minutes. 
9. The cooker was cooled to room temperature by placing it in a sink 
filled with water for 20 minutes. 
10. The slides were rinsed in distilled water for 5 minutes. 
11. They were then washed twice in phosphate buffered saline at a pH of 
7.6 for 5 minutes each. 
12. Endogenous peroxidases which may compete with the reagent 
horseradish peroxidase were blocked using hydrogen peroxide for 10-
15 minutes. 
13. The slides were washed in phosphate buffered saline for 5 minutes. 
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14. Non specific reaction of the reagent antibody with other tissue 
antigens was blocked using Power Block, which is a universal protein 
block containing casein and sodium azide. 
15.  The sections were then covered with the reagent COX-2 antibody 
and left undisturbed for an hour. 
16. Any unbound antibody present was washed off using phosphate 
buffered saline for 3 minutes.  
17. To enhance the signals produced, the sections were covered with 
Super Enhancer for 3 minutes and the slides were washed thrice in 
phosphate buffered saline for 5 minutes each.  
18. The sections were then covered with Super Sensitive Polymer HRP, 
an anti-species immunoglobulin labeled with an enzyme polymer, for 
30 minutes. 
19. The unbound antibody was removed by washing thrice in phosphate 
buffered saline. 
20. The chromogen DAB 3,3’- diaminobenzidine, was added on to the 
sections and left for 5-8 minutes, during which time a brown 
precipitate was formed. 
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21. The slides were washed thrice in phosphate buffered saline and then 
in tap water. 
22. Nuclear counterstaining was done using Mayer’s hematoxylin for 1 
minute. 
23. The slides were then washed in tap water, air dried, cleared using 
xylene and mounted with DPX. 
We used COX-2 as the primary antibody for the above procedure without 
involving any changes in any of the steps performed. We used a rabbit 
monoclonal IgG antibody (clone SP21), of Thermo Fisher Scientific make. 
It was in a ready to use form bearing a catalogue number RM-9121-R7 
(prediluted in 0.05mol/L Tris-HCL, pH 7.6 with added stabilizing protein 
and 0.015mol/L sodium azide). The lot number was 9121R1209A and its 
expiry date was 21.09.2014. We used a representative block from a case of 
colorectal cancer diagnosed in our institute as a positive control, as 
recommended by the data sheet provided by the manufacturers. 
Scoring of slides: 
The presence of representative tumor tissue in the archival blocks was 
confirmed once again by reviewing the freshly cut hematoxylin and eosin 
stained slides obtained from these blocks. The IHC slides were also  
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To reduce subjectivity in scoring the intensity of staining, we adopted the 
method described by Robert Sitarz, Roos J Leguit, Wendy WJ de Leng et 
al(65) (Figure 6).  
Accordingly, we categorized faint and diffuse cytoplasmic staining as 
‘weak’(score = 1), moderate to strong granular cytoplasmic staining as 
‘moderate’ (score = 2) and strong and diffuse cytoplasmic staining as 
‘strong’ (score = 3) (65).  
We used tissues of an old case of colon cancer that was strongly positive for 
COX-2 as a positive control.  
I did the scoring first and my guide reviewed the results.  
Based on the overall scores, the tumors were classified as negative for 
COX-2 immunostaining if the total score was 0 and positive if the scores 
ranged from 2-7. Of the positive cases, COX-2 was considered to be 
overexpressed if the total score was >4.  
Data entry: 
A master-chart was prepared. For each of the study cases, which were 
identified by a unique histopathology ID number, the following parameters 
were noted: 
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i. Age of the patient 
ii. The parity index 
iii. The menstrual status 
iv. The clinical stage 
v. The histological type of the tumor 
vi. The tumor grade, and 
vii. The extent of myometrial invasion 
Information on the first four parameters was obtained from the patients’ 
case records maintained in the Medical Records Department of the 
institution. Information on the remainder three parameters was from the 
histopathology records maintained by our department.  
We created additional columns to add the scores of intensity of IHC 
staining, percentage of cells that stained positive and the overall score to 
identify overexpression. Cases with a negative score, as well as those, which 
did not overexpress COX-2, were clubbed together as negative for 
overexpression and those cases, which had a score of four or more, were 
designated as positive for overexpression, for the purpose of statistical 
analysis. 
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Data analysis: 
The number of cases overexpressing COX-2 was expressed as a percentage 
of the total number of endometrial cancers. The COX-2 expression pattern 
was then analyzed against each of the above mentioned variables. Chi-
square test was used wherever it was found necessary to assess the level of 
significance. We assigned a ‘p’ value of <0.05 as statistically significant.   
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The study period was from 1st January, 2007 to 31st December 2013. During 
this period, the Histopathology division of the Department of Pathology 
received a total of 35,449 specimens. Thus the average biopsy load per year 
(based on the statics of the study period) was 5064. 
During this period, 3406 biopsies were reported as malignant (i.e) the 
occurrence of malignancies per year is 9.6%. Endometrial carcinomas 
accounted for 1.6% of the total malignancies (54 out of 3406).  
Of the 54 endometrial malignancies 39 cases were diagnosed on a resection 
specimen. For two of the cases, the blocks were not available. Hence, the 
study population is 37 cases of endometrial carcinoma that were diagnosed 
on resection specimens, for which blocks were available for 
immunohistochemical studies with COX-2 immunomarker.  
 An analysis of the study population showed that, the mean age at diagnosis 
was 57.5 years and the median age was 59. Majority of the patients (70%) 
were in the 6th and 7th decades of life (Figure 7).  68% of endometrial 
cancers occurred in women who have had three or less of pregnancies 
(Figure 8).  
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Immunostaining for COX-2 was performed on all the 37 cases. All but one 
of them showed expression of the immunomarker (97% expression). The 
mean score of the percentage of cells that were positive for the 
immunomarker was 3.3 (of a maximum of 4), while the mean intensity 
score was 1.7 of a maximum of 3. The mean overall score was 5 of a 
maximum of 7.  
Cases with an overall score of 4 and above were considered to be positive 
for overexpression of the COX-2 immunomarker, while those that had an 
overall score of 3 and below were considered negative for overexpression. 
Thus 78% (29 out of 37 cases) of the endometrial cancers were found to be 
overexpressive for the COX-2 immunomarker.  
As seen in table 4, 29 of the endometrial cancers were in stage I of which 21 
showed overexpression (73%). The remainders 8 were in stage II and above. 
All of them showed overexpresion (100%). The p value for COX-2 
overexpression between patients in stage I and those in stages II, III & IV is 
not significant (0.093). 
17 out of 22 cases (77%), whose histologic grade was FIGO grade I, were 
positive for overexpression of COX-2 (table 5). Similarly, 75% of the cases 
(9 out of 12) whose histologic grade was FIGO grade 2 were found  
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to be overexpressive. 100% overexpression was found in all the 3 cases 
whose histologic grade was FIGO grade 3. The p value for COX-2 
overexpression between patients in the three different histological grades 
was also not significant (0.63). 
Table 4:  COX-2 overexpression and FIGO stage 
FIGO Stage 
Positive for 
overexpression 
for COX-2 
Negative for 
overexpression 
for COX-2 
Total 
I 21 8 29 
II 3 0 3 
III 4 0 4 
IV 1 0 1 
Total 29 8 37 
 
All the 4 non endometrioid endometrial carcinomas were positive for 
overexpression of COX-2 (table 6). Of the 33 endometrioid endometrial 
carcinomas, 24% (8 cases) were positive but not overexpressive for COX-2. 
The p value for COX-2 overexpression between patients belonging to 
endometrioid and non-endometrioid groups was not significant (0.27). 
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Table 5:  COX-2 overexpression and FIGO grade 
FIGO grade 
Positive for 
overexpression 
for COX-2 
Negative for 
overexpression 
for COX-2 
Total 
I 17 5 22 
II 9 3 12 
III 3 0 3 
Total 29 8 37 
 
Table 6:  COX-2 overexpression and histologic type 
Type 
Positive for 
overexpression 
for COX-2 
Negative for 
overexpression 
for COX-2 
Total 
Endometrioid 25 8 33 
Non-
endometrioid 4 0 4 
Total 29 8 37 
 
Table 7, shows that in 7 out of 9 (78%) of the cases, where the tumor has 
invaded more than half of the myometrial thickness, there was  
overexpression for COX-2. 79% of the remainder (cases where the tumor 
invasion was less than half of the myometrial thickness) also showed  
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overexpression for COX-2.  The p value for COX-2 overexpression in 
patients with less or more than half of myometrial invasion is not significant 
(0.96). 
Table 7:  COX-2 overexpression and myometrial invasion 
Myometrial 
invasion 
Positive for 
overexpression 
for COX-2 
Negative for 
overexpression 
for COX-2 
Total 
<1/2 22 6 28 
>1/2 7 2 9 
Total 29 8 37 
 
Table 8:  COX-2 overexpression and menopausal status 
Menstrual 
status 
Positive for 
overexpression 
for COX-2 
Negative for 
overexpression 
for COX-2 
Total 
Premenopausal 4 1 5 
Postmenopausal 25 7 32 
Total 29 8 37 
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As seen in table 8, 4 out of 5 (80%) of endometrial carcinoma, that occurred 
in premenopausal women were found to be positive for overexpression of 
COX-2. 25 out of the 32 cases (78%), that occurred in postmenopausal 
women were positive for overexpression of COX-2.  The p value for COX-2 
overexpression in patients based on menopausal status is not significant 
(0.92). 
20 out of 25 cases of endometrial carcinoma (80%) that occurred in women 
whose parity (gravida status) was 3 or below, overexpressed COX-2 (table 
9). 75% of cases that occurred in women whose parity was greater than 3, 
were also positive for overexpression of COX-2. The p value for COX-2 
overexpression in patients based on parity is not significant (0.73). 
Table 9:  COX-2 overexpression and parity status 
Parity 
 
Positive for 
overexpression 
for COX-2 
Negative for 
overexpression 
for COX-2 
Total 
</= 3 20 5 25 
>3 9 3 12 
Total 29 8 37 
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PSG hospitals is a tertiary care teaching hospital affiliated to PSG Institute 
of Medical Sciences & Research, Coimbatore. The hospital is accredited by 
National Accreditation Board for Hospitals. All the diagnostic service 
laboratories, including histopathology and cytopathology are accredited by 
the National Accreditation Board for Laboratories.  
 
The hospital receives patients from the city of Coimbatore and from the 
nearby districts. It is also the higher referral hospital for its patients referred 
from its rural outreach centers.  
 
The histopathology division of the Department of Pathology receives 
specimens predominantly from patients operated within the premises of 
PSG hospitals. This is a very conducive situation for the reporting 
pathologists as the entire detail of the patients can be accessed online by a 
secure login into the Hospital Information System. The histopathology 
laboratory is categorized as a medium sized laboratory as it receives about 
20 to 40 biopsy samples per day.  
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All the samples are received in 10% buffered formalin in wide mouthed 
containers. These are usually well labeled. A test request form, filled in by a 
member of the operating team, accompanies all of the specimens. The 
samples thus received in the laboratory are immediately indexed in the 
accession register and a unique laboratory number is generated which is 
transcribed on to the request form and the container. After grossing, the 
tissues for study are processed in an automated tissue processor after which 
the paraffin blocks are prepared at an automated embedding station. The 
paraffin blocks are cut into 4-5 microns thin sections using an automated 
rotary microtome. The entire staining is also automated. Thus, the 
laboratory ensures consistency in its activities, which is crucial for an 
accurate reporting. The senior-most trained and experienced technician 
performs immunohistochemistry manually. With every batch of 
immunohistochemistry study, positive and negative control sections are also 
provided to guide the reporting.  
 
During the study period, 9.6% of the biopsy samples were reported as 
malignant. This figure may not accurately represent the occurrence of 
cancer in a tertiary care hospital because a few patients are lost to follow up 
after a clinical / radiological diagnosis of cancer. Further, some of the  
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cancers could have been reported twice- for instance, an excision biopsy 
following an initial trucut / wedge biopsy.  
 
Since 2012, the institution has developed a data base to report all cancers to 
the National Registry for Cancer. This necessitated the need for 
incorporating the ICD-O codes for all cases reported as malignant. This 
system helps to prevent over reporting of cancer incidence as patients with 
similar data are immediately identified. Hence, the institution will be in a 
better position to report the exact occurrence of cancer in the years to come. 
 
We observed that endometrial cancers accounted for 1.6% of the total 
cancers. This is almost comparable with the incidence reported by 
GLOBOCAN for endometrial carcinoma in India (2.3%), the incidence 
being adjusted for both the sexes. Some of the reasons for the lesser 
incidence in India compared to global figures could be early parity and 
multiparity. The incidence could go up as India is fast becoming the diabetic 
capital of the world, whereby women are more likely to experience 
excessive exposure to estrogens produced from peripheral fat reserves. 
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Our institution offers full time medical oncology services. These are in 
vogue since 2012. All those patients who had malignancies and required 
post operative radiotherapy usually visit one of the two radiation oncology 
centers in the city. These patients would carry with them either the slides or 
blocks to that hospital, either for confirmation of diagnosis or to perform 
additional molecular studies. Thus, of the 39 endometrial malignancies 
reported during the study period, blocks of two patients were transferred 
out. Hence, these cases had to be excluded.  
 
The median age at diagnosis of endometrial cancer in the study population 
is very similar to that reported in literature. However, 8% of our patients 
were below the age of 40 years. This is much higher than the observations 
made by Robboy(2).  However, we admit that our data is too small to be 
compared with large studies published in literature.  
 
Parity is considered an important risk factor for endometrial cancer as it 
provides estrogen free spells to the endometrium. India is experiencing an 
increasing trend towards nulliparity. This is because of more women opting 
to remain single and also due to increasing incidence of infertility. In our  
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study, only one of the patients with endometrial cancer is a nulliparous 
woman. This incidence could go higher in the future. The incidence could 
also rise as discussed earlier, due to an increasing population of obese and 
diabetic people. In our study, due to the very low incidence of nulliparity, 
we grouped the study population into two. The first group comprised of 
women who had conceived three or less number of times. Women with 
more than three conceptions were categorized as the second group. We did 
not take into account the actual parity, the number of abortions and the 
number of live children. We presumed that, conception as an event, 
provided a minimum three months estrogen free period to the endometrium. 
We observed that the majority of endometrial cancers occurred in the first 
group, thus implying the safety to the endometrium provided by a 
multiparous situation. 
 
The occurrence of endometrioid type of adenocarcinoma of the uterus is 
similar to the observations in the literature (28). Non-endometrioid type 
cancers were 11% of all endometrial cancers and comprised one each of 
mucinous, squamous, serous and clear cell types. Thus, there was no 
preponderance to a specific type. Fowler JM, Ramirez N, Cohn D et al 
found 18% of the endometrial cancers to be of the non-endometrioid type,  
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while Lambropoulou M, Alexiadis G, Limberis V et al observed that such 
neoplasms accounted for 14% of their study population (54,52). Ferrandina G, 
Legge F, Ranelletti F et al l however, have reported that only 7% of their 
study population was of the non-endometrioid type and all of them were of 
the serous type (51).  
 
About 60% of the endometrial cancers are of grade I histology (28). In our 
study, we have graded both endometrioid and non-endometrioid cancers. 
For endometrioid cancers, an architectural grade was first arrived at. This 
was followed by an assessment of the nuclear grade. We did not observe 
any of the endometrioid carcinomas to display grade III nuclear 
morphology; hence, there was no requirement to increase the overall 
histologic grade. The non-endometrioid cancers were graded based on the 
nuclear features only. All of the grade III endometrial cancers were of the 
non endometrioid type. The lone non-endometrioid cancer presenting with a 
lesser grade was of the squamous type (Grade II). 
 
FIGO stage I continues to be the most common stage at presentation for 
patients with endometrial cancers. There were eight cases whose FIGO  
Discussion 
 
90 
 
 
stage ranged from II to IV. Out of these, six were of endometrioid type and 
two were of non-endometrioid type. Both of the non-endometrioid tumors 
(squamous and mucinous) were in stage III. The other two non-
endometrioid tumors were in stage I. The endometrioid cancer, which 
presented in stage IV, had omental deposits at the time of diagnosis. 
Paradoxically, this was a multiparous woman with more than three 
conceptions. 
 
After a spate of studies on detection and significance of COX-2 expression 
in colon cancers, researchers explored the scope of investigation for non-
colon solid cancers also. Detection of COX-2 was either by 
immunohistochemistry on solid tissues, in situ hybridization and northern 
blot analysis. In 2011, researchers from the Kings Institute of Preventive 
Medicine and Research, Chennai, published their observations that, COX-2 
mRNA was overexpressed in breast cancer and lung cancer cell lines, while 
lower expression was observed in normal cell lines. They used the light 
cycler technology, which is now being considered the most precise method 
for the quantification of nucleic acid (44).  
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Shadab Mohammad, Hari Ram, Prem Narayan Gupta et al, examined the 
immunohistochemical overexpression of COX-2 in squamous cell 
carcinomas of the head and neck. They also sequentially evaluated the 
expression of COX-2 as the patients underwent radiation therapy. They 
observed that, the cases where COX-2 overexpression was observed did not 
respond effectively to radiation therapy (45).  
 
Apart from these reports, observation of COX-2 overexpression in 
malignancies of uterine cervix, prostate and stomach are also published 
from India (46,47,48). 
 
However, although western literature was available on study of 
overexpression of COX-2 in endometrial carcinomas, a thorough literature 
search performed on open search engines as well as medical databases did 
not reveal any publications from India. 
 
As discussed in the review of literature, there are many articles on the study 
of COX-2 expression in tissues which differed in their assessment of the  
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immunohistochemical staining. For instance, Fowler JM, Ramirez N, Cohn 
D et al used a simple  three tier scoring system which was more biased 
towards the intensity of cytoplasmic staining. The percentage of expression 
was kept a constant at 50%. Nasir A, Boulware D, Kaisre HE, et al. adopted 
a semi quantitative system whereby the intensity of staining and the 
proportion of cells that stained for COX-2 were scored separately. The final 
score was a mathematical derivation, which included adding up of the 
various scores found in the same tumor. This is the most appropriate method 
that would provide an accurate assessment of COX-2 overexpression. 
However, the authors have restricted the assessment to one block only. If 
the entire tumor was completely sampled and this semi quantitative system 
was to be applied, we would probably be deriving the most accurate 
information on COX-2 overexpression. As we are restricting our study to 
the assessment of one most representative block only, we preferreed to 
adopt the method proposed by Erkanli S, Bolat F, Kayaselcuk F et al. 
Accordingly, we first scored the percentage of cells that were positive for 
COX-2 expression. This was followed by an assessment of the intensity of 
staining. Whenever a higher staining intensity involving more than 25% of 
cells was noted, the score for that intensity was recorded even if the tumor 
had a larger proportion of cells with a lesser intensity of staining. 
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In our study, 97% of the endometrial carcinomas were positive for COX-2 
immunomarker, of which 78% of the endometrial carcinomas were 
overexpressive for COX-2. Tong et al, found overexpression of COX-2 in 
73% of their cases. Their sample size was small (11 cases) and they detected 
COX-2 both by immunohistochemistry and by in situ hybridization 
methods. The detection rate by both the methods was comparable (49). Nasir 
A, Boulware D, Kaiser H.E, et al, also observed a very similar incidence of 
overexpression of COX-2 in endometrial cancer (76%) in their study 
population. Thus, it is obvious that the rate of overexpression of COX-2 in 
Indian women is similar to those reported in the west (6).  
 
We observed a 100% overexpression of COX-2 in all those endometrial 
cancers that presented in stage II and above. Gabriella Ferrandina, 
Francesco Legge, Franco O. Ranelletti et al, studied the correlation between 
the overexpression of COX-2 and its clinical significance in endometrial 
carcinomas. They found that the COX-2 overexpression was higher in 
endometrial carcinomas presenting in stage II and above (61%) when 
compared with those tumors limited to the uterine corpus (51). Lambropoulou 
M, Alexiadis G, Limberis V et al, however, found a statistically significant 
association between COX-2 overexpression and FIGO stage (p=0.010). Our  
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p value is not significant (0.093). However, this could change with 
increased recruitment of cases (52).  
 
Although, many studies are evolving on assessing the association between 
those tumors that overexpressed COX-2 and mortality, we could not 
generate information on this, as our institute does not have a holistic 
oncology unit.  
 
Most of the tumors (60%) in our study had a histologic grade of I (Colour 
plates 1 and 2). Of these, 77% showed overexpression for COX-2. While 
75% of grade II tumors showed overexpression for COX-2 (Colour plates 3 
and 4), there was a 100% overexpression for COX-2 in those tumors whose 
histologic grade was III. All the grade III tumors were of the non-
endometrioid type.  
 
Although, the p value was not statistically significant, we feel the increasing 
expression with increasing grade of tumor deserves to be acknowledged. 
Serkan Erkanli, Filiz Bolat, Fazilet Kayaselcuk et al, also did not find any  
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statistically significant correlation between COX-2 overexpression and 
histologic grade of the tumor (60). However, Lambropoulou M, Alexiadis G, 
Limberis V et al, found a statistically significant correlation between 
histologic grading and COX-2 overexpression (52). Gabriella Ferrandina, 
Francesco Legge, Franco O. Ranelletti et al, found that there was an 
exponential increase in COX-2 overexpression with grade. The COX-2 
overexpression increased from 13.6% in grade I to 41.7% in grade II 
carcinomas. 61% of grade III carcinomas were positive for overexpression. 
They have also observed that this overexpression is statistically     
significant (51).  
 
Most of the studies in the literature, have analyzed the expression of COX-2 
only in the conventional endometrioid carcinomas. In Ferrandina G, Legge 
F, Ranelletti F et al’s study all of the non-endometrioid tumors were of 
serous type of which 60% were overexpressive for COX-2.  L.C. Horn, S. 
Faber, K. Bilek and C. Leo reported that their study population (8 cases) 
was only squamous cell carcinomas of corpus uteri. They observed that all 
the cases displayed overexpression for COX-2 (8). In our study, four of the 
study population (37 cases) is of non-endometrioid type and although, each  
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of them was of histologically different type, all of them were overexpressive 
for COX-2.  
 
One of the non-endometrioid tumors was of the serous type. It occurred in a 
54-year-old woman as postmenopausal bleeding. The tumor was polypoid 
and friable. It showed complex papillae lined by cells with grade III nuclei, 
invading the inner half of the myometrium. Psammoma bodies were seen 
focally. All the tumor cells were strongly immunoreactive for COX-2 with a 
diffuse cytoplasmic staining (Colour plate 5). 
 
Clear cell carcinoma was diagnosed in a 56-year-old female whose 
presentation was postmenopausal bleeding and lower abdominal pain. The 
entire uterine cavity, which was distended, was filled by a pale brown 
friable growth, that extended into the lower uterine segment and also 
infiltrated the myometrium. This tumor showed varying patterns such as 
glandular, tubulocystic, tubulopapillary and solid. Large cells with clear 
cytoplasm dominated the histological picture. A few hobnail cells were also 
seen. 75-100% of tumor cells were immunoreactive for COX-2. However, 
the intensity was diffuse and weak (Colour plate 6). 
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Mucinous carcinoma occurred in a 60-year-old woman who was admitted 
with complaints of pain abdomen for four months and brownish discharge 
for four days. The uterine cavity, which was markedly dilated, was cystic in 
consistency and contained about 200 ml of brownish viscous fluid. The wall 
was trabeculated with multiple small polyps on it. These polyps were soft 
and homogenous and appeared to be stuck on the endometrial surface. 
Histologically, the tumor showed a predominant tubular pattern. These were 
lined by mucinous epithelium with high-grade nuclei. In some areas the 
tumor cells were poorly differentiated and pleomorphic. This patient also 
had a high grade tumor confined to the fallopian tube. This could be a 
synchronous lesion. All the tumor cells display strong and diffuse 
cytoplasmic staining for COX-2 (Colour plate 7).  
 
Squamous cell carcinoma of the uterine corpus was reported in a 70-year-
old woman with postmenopausal bleeding. The tumor was polypoidal with 
fine papillary excrescences. Histologically, the tumor was composed of 
malignant squamous cells arranged in sheets, nests and finger like 
infiltrating patterns with numerous areas of necrosis. Keratin pearls were 
conspicuous in the viable areas. The tumor was found to extend up to the 
middle third of the right fallopian tube. 50-75% of the tumor cells were  
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immunoreactive to COX-2, but displayed diffuse and weak cytoplasmic 
staining only (Colour plate 8). The pattern of immunostaining observed in 
our study is very unlike those observed by Horn LC, Faber S, Bilek K and 
Leo C,, the latter had observed a diffuse and strong immunostaining in all 
the squamous cell carcinomas of the endometrium they had studied. 
 
78% of those cases where the tumor had invasion greater than half of the 
myometrium, were found to be overexpressive for COX-2. This increased 
expression of COX-2 in such tumors has been observed in almost all of the 
studies published in literature (7,51.52,53,54). While Gabriella Ferrandina, 
Francesco Legge, Franco O. Ranelletti et al (51), and Lambropoulou M, 
Alexiadis G, Limberis V et al (52), observed the association to be statistically 
significant, Jeffery M. Fowler, Nilsa Ramirez, David E. Cohn et al, did not 
find it statistically significant (54). However, Jeffery M. Fowler, Nilsa 
Ramirez, David E. Cohn et al observed that on a multivariate analysis, non-
endometrioid histology and a myometrial invasion of greater than 50% were 
predictive of advanced stage at presentation (54).  
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We observed that, the overexpression of COX-2 was almost the same 
between premenopausal women (80%) and postmenopausal women (78%). 
Thus, there is no correlation between the menopausal status and COX-2 
overexpression. There is no published information evaluating this 
parameter, although many endometrial carcinomas do occur in 
premenopausal women too.  
 
We did not find any significant difference in patients with endometrial 
carcinoma overexpressing COX-2 based on their parity. This parameter too, 
has not been evaluated in the literature.  
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SUMMARY: 
 
• During the study period (1st January, 2007 to 31st December 2013), 
the Histopathology laboratory had received a total of 35,449 biopsy 
specimens of which 3406 (9.6%) were reported as malignant. 
 
• Of these, 54 (1.6%) were reported as endometrial carcinoma.  
 
 
• The median age at presentation of patients in our study population (37 
cases) was 59 years and most of the patients were in their 6th and 7th 
decades of life. 
 
• Endometrioid carcinoma accounted for 33 of the 37 cases. The rest 
were non-endometrioid carcinoma. 
 
 
 
• 78% of the patients in our study population presented with a FIGO 
stage I disease. 
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• 97% of the endometrial carcinomas showed expression of the COX-2 
immunomarker. 
 
• Overexpression for the COX-2 immunomarker was observed in 78% 
of the cases. 
 
 
• Among the endometrioid type of endometrial cancers, 73% of cases 
overexpressed COX-2, whereas all of the non-endometrioid type 
carcinomas (100%) were observed to overexpress COX-2. 
 
• The occurrence of overexpression of the COX-2 immunomarker was 
analogous in grade I and grade II endometrial carcinomas (75-78%), 
while all of the cases that presented with a FIGO grade III lesion 
(100%) overexpressed COX-2. 
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• COX-2 overexpression did not show any significant difference 
between tumors with invasion up to less than or more than half of the 
myometrial thickness. 
 
• There was no relationship between COX-2 overexpression and 
parameters such as parity and menopausal status. 
 
CONCLUSIONS: 
 
The age group, the menopausal status, histologic grade, FIGO stage at 
presentation and the histologic type of endometrial carcinomas in our study 
was similar to those described in literature. All but one of the endometrial 
carcinomas expressed COX-2. Overexpression was consistently observed in 
all patients who presented in stage II and above. All of the non-
endometrioid carcinomas were overexpressive for COX-2. Although, we did 
not obtain a statistical significance, yet we consider that the observations are 
significant to be reported. A study of a larger cohort of population might 
elucidate statistically significant results. 
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MASTER CHART 
 
Parity: 1 = <3 & 2 =>3; Menstrual status: 1 = Postmenopausal & 2 = Premenopausal;  Type: 1 = Endometrioid carcinoma & 2 = non-endometrioid carcinoma;    
                        Myometrial invasion:  1 = <1/2 & 2 = >1/2;  Overexpression: 1 = positive & 2 = negative 
 
 
LAB NO AGE PARITY MENSTRUAL STATUS STAGE GRADE TYPE 
MYOMETRIAL 
INVASION 
SCORE OF % 
OF CELLS +ve 
INTENSITY 
SCORE 
TOTAL 
 SCORE 
OVER 
EXPRESSION 
S350/13 43 1 2 3 1 1 1 4 2 6 1 
S1002/13 77 1 1 1 1 1 1 4 1 5 1 
S1312/13 42 1 1 1 2 1 1 4 1 5 1 
S1453/13 55 1 1 1 2 1 2 4 1 5 1 
S1465/13 50 1 1 2 2 1 1 3 3 6 1 
s1630/13 70 1 1 1 2 1 1 2 1 3 2 
S1907/13 80 2 1 2 1 1 1 4 3 7 1 
S3251/13 59 2 1 1 2 1 2 4 3 7 1 
S3610/13 55 1 1 1 1 1 1 4 2 6 1 
S3619/13 44 1 2 1 1 1 1 2 1 3 2 
S3893/13 62 1 1 1 2 1 2 4 2 6 1 
S4364/13 60 2 1 1 1 1 1 4 3 7 1 
S4570/13 64 1 1 1 2 1 2 3 1 4 1 
S4732/13 61 1 1 1 2 1 1 4 3 7 1 
S394/12 63 2 1 4 2 1 1 3 1 4 1 
S1261/12 73 2 1 1 1 1 1 4 1 5 1 
 
 
MASTER CHART 
 
Parity: 1 = <3 & 2 =>3; Menstrual status: 1 = Postmenopausal & 2 = Premenopausal;  Type: 1 = Endometrioid carcinoma & 2 = non-endometrioid carcinoma;    
                        Myometrial invasion:  1 = <1/2 & 2 = >1/2;  Overexpression: 1 = positive & 2 = negative 
 
 
 
LAB NO AGE PARITY MENSTRUAL STATUS STAGE GRADE TYPE 
MYOMETRIAL 
INVASION 
SCORE OF % 
OF CELLS +ve 
INTENSITY 
SCORE 
TOTAL 
 SCORE 
OVER 
EXPRESSION 
S2113/12 66 2 1 1 2 1 1 2 1 3 2 
S4078/12 67 1 1 1 1 1 1 4 2 6 1 
S4328/12 60 1 1 1 1 1 1 4 1 5 1 
S2602/11 60 2 1 3 3 2 2 4 3 7 1 
S3996/11 59 1 1 1 1 1 1 2 1 3 2 
S4579/11 58 1 1 1 1 1 1 4 2 6 1 
S4890/11 70 2 1 3 2 2 2 3 1 4 1 
S3583/10 24 1 2 2 1 1 1 4 3 7 1 
S3706/10 52 1 1 1 1 1 1 4 2 6 1 
S3898/10 50 1 1 1 1 1 2 1 1 2 2 
S4393/10 60 1 1 1 1 1 2 1 1 2 2 
S4597/10 27 1 2 1 1 1 1 4 2 6 1 
S4714/10 58 2 1 1 1 1 1 3 2 5 1 
S1116/09 53 1 1 1 3 2 2 4 1 5 1 
S1014/08 54 2 1 1 3 2 1 4 3 7 1 
S1355/08 29 1 2 1 1 1 1 4 2 6 1 
S2627/08 57 1 1 1 1 1 1 3 1 4 1 
 
MASTER CHART 
 
Parity: 1 = <3 & 2 =>3; Menstrual status: 1 = Postmenopausal & 2 = Premenopausal;  Type: 1 = Endometrioid carcinoma & 2 = non-endometrioid carcinoma;    
                        Myometrial invasion:  1 = <1/2 & 2 = >1/2;  Overexpression: 1 = positive & 2 = negative 
 
 
 
LAB NO AGE PARITY MENSTRUAL STATUS STAGE GRADE TYPE 
MYOMETRIAL 
INVASION 
SCORE OF % 
OF CELLS +ve 
INTENSITY 
SCORE 
TOTAL 
 SCORE 
OVER 
EXPRESSION 
S3326/08 55 1 1 3 1 1 1 4 3 7 1 
S165/07 70 1 1 1 1 1 1 4 2 6 1 
S520/07 59 2 1 1 2 1 1 2 1 3 2 
S1224/07 72 2 1 1 1 1 1 0 0 0 2 
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